Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer and carries the worst prognosis of all common cancers. Five-year survival rates have not surpassed 6% for some decades and this lack of improvement in outcome urges a better understanding of the PDAC-specific features which contribute to this poor result. One of the most defining features of PDAC known to contribute to its progression is the abundance of non-tumor cells and material collectively known as the stroma. It is now well recognized that the different non-cancer cell types, signalling molecules, and mechanical properties within a tumor can have both tumor-promoting as well as –inhibitory effects. However, the net effect of this intratumour heterogeneity is not well understood. Heterogeneity in the stromal makeup between patients is even less well established. Such intertumour heterogeneity is likely to be affected by the relative contributions of individual stromal constituents, but how these contributions exactly relate to existing classifications that demarcate intertumour heterogeneity in PDAC is not fully known. In this review, we give an overview of the available evidence by delineating the elements of the PDAC stroma and their contribution to tumour growth. We do so by interpreting the heterogeneity at the gene expression level in PDAC, and how stromal elements contribute to, or interconnect, with this.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The extracellular matrix at a glance
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.023820 · Cited by 4,334 · cited 1×
“The extracellular matrix (ECM) is the principal non-cellular component of the fibrotic stroma, and is composed of collagens, glycosaminoglycans, proteoglycans, and growth factors [7,8].”
BackgroundGenomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 8×
“High purity Low purity Bailey [32] Stroma normal Stroma activated Common subtypes Other subtypes”
BackgroundMethodInfluentialThe extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“The extracellular matrix (ECM) is the principal non-cellular component of the fibrotic stroma, and is composed of collagens, glycosaminoglycans, proteoglycans, and growth factors [7,8].”
BackgroundMonocyte recruitment during infection and inflammation
Shi, C., & Pamer, E. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3070 · Cited by 3,015 · cited 1×
“Monocytes migrate to the tissue following chemoattractant signals and extravasate from the blood vessels and undergo differentiation into macrophages [124].”
BackgroundÖzdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“These 4 subtypes range from stable, locally rearranged, scattered, to an unstable subtype, all referring to the degree of structural variations present in the genome [21].”
BackgroundAssociation of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 2×
“Activating mutations in KRAS are a hallmark of PDAC, and are found in nearly 95% of cases [15,16].”
BackgroundHyaluronan: its nature, distribution, functions and turnover.
Fraser, J. R. E., Laurent, T. C., & Laurent, U. B. G. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.00170.x · Cited by 2,031 · cited 1×
“It is formed in the plasma membrane instead of the Golgi membranes, allowing for large HA chains to be formed [54].”
BackgroundSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Cox, T. R., & Erler, J. T. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.004077 · Cited by 1,569
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion
Sousa, C. M., Biancur, D. E., Wang, X., Halbrook, C. J., Sherman, M. H., Zhang, L., Kremer, D., Hwang, R. F., Witkiewicz, A. K., Ying, H., et al. (2016) · Nature · doi:10.1038/nature19084 · Cited by 1,122 · cited 1×
“This autophagy of PSCs facilitates as a nutrient source for the cancer cells by providing them with non-essential amino acids (NEAA) such as alanine [78,79].”
BackgroundKamphorst, J. J., Nofal, M., Commisso, C., Hackett, S. R., Lu, W., Grabocka, E., Vander Heiden, M. G., Miller, G., Drebin, J. A., Bar-Sagi, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2211 · Cited by 893
Carstens, J. L., Correa de Sampaio, P., Yang, D., Barua, S., Wang, H., Rao, A., Allison, J. P., LeBleu, V. S., & Kalluri, R. (2017) · Nature Communications · doi:10.1038/ncomms15095 · Cited by 633
Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells
Apte, M. V., Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., Ramm, G. A., Buchler, M., Friess, H., McCarroll, J. A., et al. (2004) · Pancreas · doi:10.1097/00006676-200410000-00002 · Cited by 591 · cited 1×
“The stroma can constitute up to 90% of the tumour bulk and is characterized by extensive fibrosis, lack of vascularization, immune infiltrates, and hypoxia [5].”
BackgroundEne–Obong, A., Clear, A. J., Watt, J., Wang, J., Fatah, R., Riches, J. C., Marshall, J. F., Chin–Aleong, J., Chelala, C., Gribben, J. G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.025 · Cited by 579 · cited 1×
“Tumour cells prevent the infiltration of these anti-tumour lymphocytes, as the juxtastroma hampers the functionality of cytotoxic T cells [146].”
BackgroundHalper, J., & Kjaer, M. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-7893-1_3 · Cited by 532
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
Notta, F., Chan-Seng-Yue, M., Lemire, M., Li, Y., Wilson, G. W., Connor, A. A., Denroche, R. E., Liang, S.-B., Brown, A. M. K., Kim, J. C., et al. (2016) · Nature · doi:10.1038/nature19823 · Cited by 528 · cited 1×
“It should be noted that this concept of gradual mutational burden was recently challenged; it has been suggested that mutations occur in a relatively rapid sequence of large genetic events [14].”
BackgroundGenetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502 · cited 1×
“Later pre-clinical research has shown that when ablating a-SMA positive fibroblasts [118], knocking out SHH ligand [119], or pharmacological inhibition of the Hh pathway [120] increased the aggressive behaviour of tumour cells.”
BackgroundOlivares, O., Mayers, J. R., Gouirand, V., Torrence, M. E., Gicquel, T., Borge, L., Lac, S., Roques, J., Lavaut, M.-N., Berthezène, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16031 · Cited by 413 · cited 1×
“Further nutrient sources come via the uptake of collagen I- and V-derived proline from the ECM, for entry in the tricarboxylic acid (TCA) cycle or glutamine synthesis [77].”
BackgroundLongati, P., Jia, X., Eimer, J., Wagman, A., Witt, M.-R., Rehnmark, S., Verbeke, C., Toftgård, R., Löhr, M., & Heuchel, R. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-95 · Cited by 394 · cited 2×
“The increased presence of ECM proteins in 3D cultures is thought to support this chemoresistance, via cell adhesion mediated drug resistance (CAM-DR) [59].”
BackgroundThe hypoxic tumour microenvironment and metastatic progression
Subarsky, P., & Hill, R. P. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022939318102 · Cited by 327 · cited 1×
“This results from the abundant and dense stroma that compresses existing capillaries, and leads to hypoxia and nutrient depletion [68].”
BackgroundZhao, X., Gao, S., Ren, H., Sun, W., Zhang, H., Sun, J., Yang, S., & Hao, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3009 · Cited by 163 · cited 1×
“All promote tumour cell migration and invasion [85,86].”
Background
Cited by
Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Orth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
Li, D., Chen, X., Dai, W., Jin, Q., Wang, D., Ji, J., & Tang, B. Z. (2024) · Advanced Materials · doi:10.1002/adma.202306476 · Cited by 93
A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment
Geyer, M., Schreyer, D., Gaul, L.-M., Pfeffer, S., Pilarsky, C., & Queiroz, K. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01334-z · Cited by 61
Metadata
- Authors
- Veenstra, V., Garcia-Garijo, A., Van Laarhoven, H., & Bijlsma, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-01-27
- Volume
- 10
- Issue
- 2
- Pages
- 34
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2787497429
- Cited by
- 52
- References
- 28
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.